Opportunities for developing therapies for rare genetic diseases: focus on gain-of-function and allostery

Abstract

BackgroundAdvances in next generation sequencing technologies have revolutionized our ability to discover the causes of rare genetic diseases. However, developing treatments for these diseases remains challenging. In fact, when we systematically analyze the US FDA orphan drug list, we find that only 8% of rare diseases have an FDA-designated drug. Our approach leverages three primary insights: first, diseases with gain-of-function mutations and late onset are more likely to have drug options; second, drugs are more often inhibitors than activators; and third, some disease-causing proteins can be rescued by allosteric activators in diseases due to loss-of-function mutations.ResultsWe have developed a pipeline that combines natural language processing and human curation to mine promising targets for drug development from the Online Mendelian Inheritance in Man (OMIM) database. This pipeline targets diseases caused by well-characterized gain-of-function mutations or loss-of-function proteins with known allosteric activators. Applying this pipeline across thousands of rare genetic diseases, we discover 34 rare genetic diseases that are promising candidates for drug development.ConclusionOur analysis has revealed uneven coverage of rare diseases in the current US FDA orphan drug space. Diseases with gain-of-function mutations or loss-of-function mutations and known allosteric activators should be prioritized for drug treatments.Electronic supplementary materialThe online version of this article (doi:10.1186/s13023-017-0614-4) contains supplementary material, which is available to authorized users.

Antisense oligonucleotide modulation of non-productive alternative splicing upregulates gene expression

“…Autosomal dominant diseases are further divided into haploinsufficiency (the mutant allele leads to loss of function) or dominant-negative/gain-of-function (the mutant allele leads directly to a toxic function). Current therapeutic approaches address as little as 5% of these diseases and the majority are only addressing patient symptoms 1 , 2 . Most monogenic disorders are caused by reduced expression or deficient proteins.…”

Rare Renal Disease in Macedonia – An Update

“…An important strategy when developing drugs is to use small molecule drugs which can inhibit their targets. Unfortunately, majority of single gene mutations lead to loss of function which is more difficult from pharmaceutical aspect in order to create agonist/activators which can save the function of the altered protein [9]. The database of DrugBank contains a library of 1700 small molecules but only 423 are agonist/ activators [10].…”

Drug Repositioning for Noonan and LEOPARD Syndromes by Integrating Transcriptomics With a Structure-Based Approach

“…(2011) comprehensively compared disease gene signatures to drug transcriptomic signatures from CMap to suggest the potential reuse of the anticonvulsant topiramate for inflammatory bowel disease (IBD) treatment. Also, some other approaches such as information retrieval or text mining ( Chen and Altman, 2017 ), miRNA transcription factor feed-forward loops ( Liu et al., 2014 ), and high throughput or high content screening assays ( Bellomo et al., 2017 ) have also been applied to drug repositioning of rare diseases.…”